Profil
Jose Olague worked as a Director of Manufacturing Engineering & Maintenance at Intarcia Therapeutics, Inc. and as a Director of Manufacturing & Engineering at Avinger, Inc. He also served as the Vice President of Engineering at Alpha Teknova, Inc. from 2020 to 2023.
Mr. Olague obtained an undergraduate degree from Instituto Tecnológico de Ciudad Juárez.
Anciens postes connus de Jose Olague
| Sociétés | Poste | Fin |
|---|---|---|
| ALPHA TEKNOVA, INC. | Directeur Technique/Scientifique/R&D | 01/09/2023 |
| AVINGER, INC. | Corporate Officer/Principal | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Formation de Jose Olague
| Instituto Tecnológico de Ciudad Juárez | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ALPHA TEKNOVA, INC. | Health Technology |
| AVINGER, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
